The biotech industry is poised for long-term growth due to growing healthcare needs, a rapidly aging population, the need for personalized treatments and therapies, and the use of advanced technologies to accelerate drug development.
However, it could be wise to wait for a better entry point in TG Therapeutics, Inc. (TGTX) and Galapagos NV (GLPG). On the other hand, investors could consider buying fundamentally strong BioMarin Pharmaceutical Inc. (BMRN) and United Therapeutics Corporation (UTHR).
